|$386,386||To research Medicaid spending on prescription drugs under FDA's accelerated approval pathway with unclear clinical benefits.||2020 - 2022||LJAF|
|$280,385||To provide stakeholders with transparent information about Food and Drug Administration approved and experimental medications.||2020 - 2022||LJAF|
|$359,808||To advance the implementation and rigorous testing of deferred prosecution programs.||2016 - 2018||LJAF|
Have an evidence-based week
Get The Abstract from Arnold Ventures delivered to your inbox.